



eve investments

Omniblend Innovation Acquisition

February 2016

Disclaimer

For personal use only

- The information contained in this presentation is not financial product advice. The presentation is for information purposes and is of a general and summary nature only. It does not constitute an offer. EVE Investments Limited (EVE) gives no warranties in relation to the statements and information in this presentation. Investors should seek appropriate advice on their own objectives, financial situation and needs.
- This presentation contains certain statements which may constitute “forward-looking statements”. Such statements are only predictions and are subject to inherent risks and uncertainties which could cause actual values, performance or achievements to differ materially from those expressed, implied or projected in any forward looking statements.
- EVE disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise. Investors are cautioned that forward-looking statements are not guarantees of future performance and investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.
- This presentation does not constitute or form any part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities in the Company nor shall it or any part of it, or the fact of its distribution, form the basis of, or be relied on in connection with, any contract or commitment or investment decision relating to any securities in the Company. Any decision regarding any proposed subscription for securities in the Company must be made solely on the basis of information on the Company that is publicly available.



Who is Eve Investments?

- ASX listed technology investment company (ASX Code: EVE)
- Targeted investment focus - early stage technology investments with global market potential
- Clear objective – fund opportunities through to IPO with 2 year time horizon
- Status – first investment planned following review of over 80 potential opportunities

Board of Directors & Management

- Alasdair Cooke, Executive Chairman
- Bill Fry, Executive Director
- Michael Curnow, Non-executive Director
- Ben Rohr, Investment Director
- Steven Jackson, Company Secretary

Capital Structure

Ordinary Shares:	743,666,723
Placement:	Complete
Unlisted Options:	80,000,000 ex @ 2c, exp 31 Dec 16
Market Cap:	A\$3.9 million (18 Dec)
Cash:	A\$0.7 million (18 Dec + placement cash)
Debt:	Nil

Key Shareholders

Directors and Management	30%
Geared Investments	4%
Henry Deburgh	4%
Donal Windrim	4%

EVE top 20 shareholders own approximately 68% of Company



Acquisition Summary

For personal use only

- Omniblend Innovation is an innovative medical technology company focused on foods for special medical purposes
- Flagship product, GlucoControl, a patented food-grade pre-meal drink offering a unique management option for people living with type 2 diabetes (T2D)
- EVE Investments has entered into a binding agreement to acquire an initial ~ 40% ownership in Omniblend Innovation Pty Ltd
 - 1st Tranche –\$ 1,625,000 in Feb 2016
 - 2nd Tranche - \$1,625,000 in Jun 2016
- EVE Investments have the right to publicly list Omniblend Innovation within 2 years
- EVE shareholders receive a preferential entitlement in any IPO/RTO



Investment Rationale – Omniblend Innovation

For personal use only

- ✓ **Significant global market opportunity** - over 387 million adults living with T2D
 - ✓ Phase 1 – Australia & NZ
 - ✓ Phase 2 – China
- ✓ **Highly differentiated and affordable** product offering
- ✓ **Strong clinical validation** - with GlucoControl shown to reduce blood glucose level peaks by 35% after carbohydrate containing meals
- ✓ **Major distribution partner validates commercial potential** - exclusive 6-year distribution agreement with a national pharmacy distributor
- ✓ **Imminent commercialisation and cash flow** – product to reach more than 6,000 pharmacy shelves in Australia and New Zealand by mid 2016
- ✓ **Strong defensibility** – patent protection in place
- ✓ **Robust revenue model** – gross profit of at least 20c on each unit sold
- ✓ **Highly activity newsflow pipeline** – next 12 months includes national product launch & Chinese expansion



Who is Omniblend Innovation?

Overview

1

Developer of food based products for special medical purposes

2

All food grade products used

3

Flagship product clinically proven for type 2 diabetes glucose control

4

Strong pipeline of other products in development

5

Clinical trials validation of products

6

Awarded a substantial Commercialisation Australia grant (\$1.35m)

Experienced Management Team

Arie Nudel: Managing Director

Over 12 years experience in nutritional supplement development, manufacture and sales. Principal of Omniblend Nourish the infant formula and export company of Australian made powdered dairy nutritional product to China.

Dr Gottfried Lichti: Founder, Director & Head of Research & Development

Leading agribusiness technology and biological formulation developer, for over 30 years. PhD in physical and polymer chemistry from Sydney University.



Lead Product –GlucoControl

For personal use only

- **GlucoControl** – “Foods for Special Medical Purposes” FSANZ 2.9.5
- Food-grade drink taken before selected meals to **reduce elevated blood glucose** after the meal
- Taking GlucoControl™ before a high-GI (Glycemic Index) meal provides 3 main benefits:
 - The **GI** of the drink/meal combination is **reduced by 33-38%**
 - The soluble-fibre content is **increased** by 5 grams; and
 - **Feelings of fullness** are enhanced



Type 2 diabetes is a progressive condition (insulin resistance)


Diet and exercise are the best methods for managing the disease outside of prescription medication



Clinically Validated

For personal use only


- **Red Line** – No OI Pre-meal, average
- **Blue Line** – GlucoControl average (OI Pre-meal consumed 15 min before meal)
- Results have been confirmed, with similar results achieved in University of Adelaide run studies



Significant Global Market Opportunity

For personal use only

- **Globally** there are over **415m people with Diabetes**, accounting for 12% of global health expenditure **>USD673 billion**
- Rapid growth seen in **China**:
 - In 1980, less than 1% of **Chinese** adults had diabetes, but this increased to almost 12% (**113.9 million adults**) by 2010
 - Estimates indicate that around **half of Chinese adults have pre-diabetes**, putting them at high risk of diabetes (Source: *AsianScientist*, Sep. 17, 2014)
- Other significant markets:
 - **US 29.1m people**
 - **India 65.1m people**
 - **Australia 1.4m people**



Infant Milk Comparison

There are about **51m infants in China** that can be targeted for the **powdered infant milk formulation market**



Unique Protected Product Offering

No known equivalent non-pharmaceutical **product** that is commercial viable exists in Australia or elsewhere



Granted patent application (no 2012904029) in Australia



Granted patent application (2014/08480) in South Africa



Provisional Patent applicant (no 61/650769) in the US both for a Composition and Method for Management of Diabetes or Pre-Diabetes

Strong Patent Protection



Imminent Australian Commercialisation

For personal use only



National Pharmacy Distributor (Endeavour) accessing over 6,000 pharmacy channels across Australia and NZ



Manufacturing commenced in January and product roll-out in **March 2016** under the **Faulding's** brand



Lean Revenue model – contract manufacture, distribution & marketing



Retail **price** of approximately \$3.50 ex gst and which is **comparable to single serve dietary products**



Product is **supported by key health and diet opinion leaders** and positive clinical study results



Global Distribution & Revenue Model


For personal use only

- International licensing & **distribution negotiations** have **commenced** in **China & Europe**
- Global Revenue model is focused on **royalty based marketing & distribution partnerships** for larger export markets
- **Currently** negotiating in **China** with a **number of regional distributors** including Guangdong, Shanghai, Beijing, Qiannan, Hebei and Taiwan
- In the **US & Europe** Omniblend Innovation will negotiate License & Sale Agreements with **key regional players** such as: Nestle (Switzerland), Unilever (UK), Glambia (Ireland), Abbot Nutrition (US), Chr. Hansen (Denmark), Dupont (US/Denmark), Tate & Lyle plc (UK), Corbion N.V. (Netherlands)



Revenue Forecasts for GlucoControl

For personal use only



Global revenue is forecast to be between
A\$80m - A\$100m by the end of 2020



Strong Pipeline of Future Products

Omniblend has a **number of additional products** that could be ready for commercialisation within the **next 12-24 months**, including:

Pre-meal drink for aged care



- Undergone extensive work and a formulation is **ready for Clinical trials**
- Product helps **maintain blood pressure and cognition** post consumption of a meal

Pre-meal drink for ante-natal maternal care



- Pre-meal drink will provide a boost in (i) calcium, (ii) folate, (iii) iron and (iv) fibre
- Retains glycaemic-reduction properties to achieve more favourable blood glucose profiles



Funding Overview

For personal use only

A **\$500,000 placement** at \$0.005 per share was completed in **late 2015**

A **non-renounceable rights issue** to raise approximately **\$1.5m** will be completed in **mid-late February** to fund the first investment Tranche

Eve Investments is **currently assessing offers** to **underwrite** the rights issue

Eve Investments has already received a number of **commitments** from **shareholders** to **participate** in the rights issue



Summary & Outlook

For personal use only

- Omniblend Innovation's lead product is a patent protected pre-meal drink targeting a massive global population of over 387m people with type 2 diabetes
- Clinically proven product, with no commercially viable competitors
- Imminent product launch in Australia through a major pharmacy distribution network
- Significant phase two opportunity in China
 - Negotiations for a distribution partner in China are progressed
 - Omniblend Innovation management experienced in selling Australian products into the Chinese Market
- Omniblend has a solid pipeline of future products to continue growth
- EVE Investments has the right to take the company Public





eve investments

Thank you